<DOC>
	<DOC>NCT02991118</DOC>
	<brief_summary>The purpose of this study is to see if bemedoic acid (ETC-1002) is effective versus placebo in patients with high cardiovascular risk and elevated LDL cholesterol not adequately controlled by their current therapy.</brief_summary>
	<brief_title>Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Fasting LDLC ≥100 mg/dL High cardiovascular risk (diagnosis of HeFH and/or ASCVD) Be on maximally tolerated lipidmodifying therapy Total fasting triglyceride ≥500 mg/dL Renal dysfunction or nephrotic syndrome or history of nephritis Body Mass Index (BMI) ≥50kg/m2 Significant cardiovascular disease or cardiovascular event in the past 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>hyperlipidemia</keyword>
	<keyword>cholesterol</keyword>
	<keyword>familial hypercholesterolemia</keyword>
	<keyword>atherosclerotic cardiovascular disease</keyword>
	<keyword>ASCVD</keyword>
	<keyword>HeFH</keyword>
	<keyword>LDL</keyword>
</DOC>